
    
      Primary Objective:To establish the response rate using RECIST 1 criteria to weekly TPC in
      patients with metastatic or relapsed squamous cell carcinoma of the head and neck Secondary
      Objective: To establish the safety profile, progression free and overall survival of weekly
      TPC in this patient population.
    
  